CERRITOS, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), one of the largest value-based oncology practices in the country, today announced that Dr. Daniel Virnich, TOI’s Chief Executive Officer, will participate at the following investor conferences:
Jefferies Global Healthcare Conference
Date: June 6th, 2024
Fireside Chat: 9:00am Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: New York City, NY
Truist Securities Healthcare Disruptors & Digital Health Summit
Date: June 26th, 2024
Panel: 1:00pm Eastern Time
TOI Participant: Daniel Virnich, M.D., MBA, Chief Executive Officer
Location: New York City, NY
Interested investors and other parties may listen to simultaneous webcasts of the presentations by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/. The online replay will be available for a limited time shortly following the call.
About The Oncology Institute, Inc.
Founded in 2007, The Oncology Institute, Inc. and its affiliates (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.8 million patients including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With 110+ employed clinicians and over 70 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.
Contacts
Investors
Solebury Strategic Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$3.73 |
Daily Change: | 0.06 1.63 |
Daily Volume: | 1,570,890 |
Market Cap: | US$342.820M |
June 30, 2025 May 14, 2025 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORERecursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREEnd of content
No more pages to load